Avandia, Actos Add Black Box; RECORD Leaves Heart Attack Risk Unresolved
Executive Summary
FDA is adding a "black box" warning about the risk of congestive heart failure to thiazolidinediones while it continues to evaluate the potential risk of myocardial infarction seen in the class of type 2 diabetes therapies
You may also be interested in...
Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health
Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years
Drug Safety Concerns Help Depress U.S. Sales Forecasts From IMS Health
Drug safety concerns contributed to IMS Health's decision to lower its forecast for the compound annual pharmaceutical sales growth rate over the next several years
Avandia Adds Black Box For Heart Attack Risk; Actos Launches Ads
FDA has unveiled the much-anticipated labeling change for GlaxoSmithKline's type 2 diabetes therapy Avandia, but is deeming the information about rosiglitzone's cardiovascular risk "inconclusive" and is asking the sponsor to undertake a long-term outcomes study to address outstanding safety questions